MARKET

IKT

IKT

Inhibikase Therapeutics Inc
NASDAQ
1.680
+0.110
+7.01%
After Hours: 1.680 0 0.00% 16:10 05/20 EDT
OPEN
1.580
PREV CLOSE
1.570
HIGH
1.695
LOW
1.570
VOLUME
674.35K
TURNOVER
--
52 WEEK HIGH
2.260
52 WEEK LOW
1.330
MARKET CAP
221.81M
P/E (TTM)
-3.8113
1D
5D
1M
3M
1Y
5Y
1D
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 1d ago
Inhibikase Therapeutics (IKT) Gets a Buy from Cantor Fitzgerald
TipRanks · 1d ago
Weekly Report: what happened at IKT last week (0511-0515)?
Weekly Report · 2d ago
LifeSci Capital Keeps Their Buy Rating on Inhibikase Therapeutics (IKT)
TipRanks · 4d ago
Analysts Are Bullish on These Healthcare Stocks: Milestone Scientific (MLSS), Inhibikase Therapeutics (IKT)
TipRanks · 5d ago
Bank of America Securities Reaffirms Their Buy Rating on Inhibikase Therapeutics (IKT)
TipRanks · 5d ago
Analyst Flags High Risk in Inhibikase Therapeutics Stock, Urges Investors to Review 2025 Form 10-K Risk Factors
TipRanks · 6d ago
Analysts Offer Insights on Healthcare Companies: Inhibikase Therapeutics (IKT) and PepGen Inc. (PEPG)
TipRanks · 05/13 14:30
More
About IKT
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).

Webull offers Inhibikase Therapeutics Inc stock information, including NASDAQ: IKT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IKT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IKT stock methods without spending real money on the virtual paper trading platform.